Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system attacks the body’s own tissues. About 50% of people with lupus develop this complication, making it one of the most serious ways lupus can affect the body. When the kidneys become a target, they lose their ability to filter waste and excess fluid properly, which can lead to a cascade of other health problems if not treated.
How Lupus Damages the Kidneys
In a healthy immune system, antibodies target foreign invaders like bacteria and viruses. In lupus, the immune system produces antibodies that mistakenly attack the body’s own DNA. These rogue antibodies latch onto fragments of DNA floating in the bloodstream, forming clumps called immune complexes. Those clumps then get deposited in the tiny filtering units of the kidneys, called glomeruli.
Once lodged there, these immune complexes trigger a chain reaction. They activate the complement system (a set of proteins that normally helps clear infections), which draws in waves of inflammatory cells. The resulting inflammation damages the delicate structures that filter your blood. Over time, the damage can spread. The immune system initially targets one part of the kidney’s filtering membrane, then expands to attack additional structures through a process called epitope spreading. This is why lupus nephritis tends to worsen in stages: deposits first appear in the central support tissue of the glomeruli, then progress to deeper layers, causing increasingly severe damage.
People with lupus who also have antiphospholipid syndrome face an additional risk. Antibodies can interact with proteins on blood vessel walls, promoting clot formation inside the kidneys and further restricting blood flow.
Who Is Most at Risk
Lupus itself disproportionately affects women, with a female-to-male ratio of roughly 10 to 15 for every 1 male case. It is also more than three times as common in Black individuals compared with white individuals. Among those who develop lupus, the people most likely to progress to kidney involvement tend to be younger (averaging around age 38 at diagnosis of nephritis versus 47 for those who don’t develop it) and are more likely to be of Asian, Black, or Hispanic background. In one large cohort study, Asian patients made up 33% of those who developed lupus nephritis within five years, despite representing only 17% of the overall lupus population. Hispanic patients were similarly overrepresented.
Symptoms to Recognize
Lupus nephritis often develops quietly. The kidneys can lose a significant amount of function before symptoms become obvious. When signs do appear, they typically include:
- Foamy urine, caused by excess protein leaking through damaged kidney filters
- Blood in the urine, which may be visible or only detectable on a lab test
- Swelling in the legs, ankles, feet, hands, or face, from fluid the kidneys can no longer remove efficiently
- High blood pressure, which can develop suddenly or worsen from previously normal levels
Many people discover they have lupus nephritis through routine blood and urine tests before they notice any of these changes. Rising creatinine levels in the blood (a waste product normally cleared by healthy kidneys) are one of the earliest lab clues.
How It Is Diagnosed
Standard blood and urine tests can raise suspicion, but they have limitations. Measures like protein in the urine and estimated kidney filtration rate often don’t flag a problem until some irreversible damage has already occurred. A kidney biopsy remains the gold standard for confirming the diagnosis. During this procedure, a small needle removes a tiny sample of kidney tissue, which is then examined under a microscope to determine exactly how the kidneys are being affected.
The biopsy results are classified into six categories, known as the ISN/RPS system, ranging from class I (minimal involvement with deposits only in the central support tissue) to class VI (advanced scarring where more than 90% of the filtering units are permanently damaged). Classes III and IV, where inflammation is widespread across many glomeruli, are the most common forms requiring aggressive treatment. Class V involves a different pattern where immune deposits settle along the outer edge of the filtering membrane, causing heavy protein loss. Knowing the class matters because it directly determines how treatment is approached.
Cardiovascular Risks
Kidney involvement in lupus doesn’t just threaten the kidneys. It dramatically raises the risk of heart disease and other vascular problems. People with lupus nephritis are about five times more likely to develop high blood pressure compared to lupus patients without kidney involvement. Up to 80% of lupus nephritis patients have elevated blood pressure. They also face an 11-fold higher risk of developing abnormal cholesterol levels and nearly double the risk of diabetes.
These combined risk factors take a measurable toll. Cardiovascular death occurs at a rate of roughly 11.7 per 1,000 patient-years in people with lupus nephritis, compared to 3.6 per 1,000 patient-years in lupus patients whose kidneys are spared. Women with lupus between ages 35 and 44 have a risk of heart attack 50 times higher than the general population. Managing blood pressure, cholesterol, and blood sugar becomes just as important as treating the kidney disease itself.
Treatment Approach
Treatment unfolds in two phases: induction (bringing the active inflammation under control) and maintenance (keeping it from coming back).
Induction Therapy
The initial goal is to suppress the immune attack on the kidneys as quickly as possible. This typically involves high-dose steroids combined with a second immunosuppressive medication. The specific combination depends on the severity and class of disease. A “multitarget” approach using two immunosuppressants together has shown particularly strong results, more than doubling complete remission rates compared with older single-drug regimens in some studies.
Maintenance Therapy
Once inflammation is controlled, the focus shifts to preventing flares while gradually tapering steroids. The long-term use of steroids carries its own serious side effects, so getting patients to the lowest effective dose is a priority. Maintenance medications that help prevent relapse are continued for years, though the optimal duration remains an individual decision.
Newer Targeted Therapies
Two treatments approved in 2020 and 2021 have expanded the options. Belimumab, which blocks a protein that helps rogue immune B cells survive, improved complete kidney response rates at two years when added to standard therapy. It also helped more patients taper to very low steroid doses (37% versus 28% on standard therapy alone). Voclosporin, an oral medication that calms the overactive immune response in the kidneys, nearly doubled complete response rates at one year. Both drugs showed side effect profiles comparable to existing treatments, though voclosporin carries warnings about potential kidney toxicity with prolonged use and requires monitoring to confirm it’s working (typically a 50% reduction in protein leakage within 6 to 12 months).
Diet and Lifestyle Considerations
A low-sodium diet is important for managing the high blood pressure that accompanies most cases of lupus nephritis. Because cardiovascular risk is so elevated in this population, keeping dietary cholesterol and saturated fat low is equally critical. Raw vegetables make a good go-to snack, ideally paired with lighter options like hummus rather than high-fat dips. These changes won’t replace medication, but they reduce the overall burden on kidneys and blood vessels that are already under stress.
Maintaining a healthy weight, staying physically active within your limits during flares, and closely tracking blood pressure at home all contribute to better long-term outcomes. Because lupus nephritis tends to flare and remit, consistent monitoring through regular lab work is essential even during periods when you feel well.